EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world comparative effectiveness of evolocumab versus ezetimibe in adults with atherosclerotic cardiovascular disease: an active-comparator new-user study

Nihar Desai, Ran Jin, Kathleen Hurwitz, Nafeesa N. Dhalwani, Nuvan Rathnayaka, Shia T. Kent, Neil A. Accortt, Timothy L. Lash, Paul Muntner, Chris P. Gale, Ann Marie Navar, M. Alan Brookhart

American Journal of Preventive Cardiology · 2026-11 · 102577

DOI: 10.1016/j.ajpc.2026.102577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-11. Verfasst von Nihar Desai und 11 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evolocumab and ezetimibe are both guideline-recommended options for patients unable to reach LDL-C goals on statin therapy. While both have been shown to lower cardiovascular risk, head-to-head outcomes data are lacking.

Methods

We conducted an active-comparator, new-user cohort, target trial emulation study using the U.S. Komodo Health Healthcare Map® database among patients with ASCVD and any prior statin use who initiated evolocumab or ezetimibe during 2017–2024. Follow-up continued through June 2026. Using inverse probability weighting for treatment and informative censoring, we estimated the 4-year cumulative risks of fatal or nonfatal MI for each treatment group and compared hazards using a hazard ratio (HR) estimator that incorporated baseline LDL-C, where available, and accounted for missing baseline LDL-C, where not available.

Results

The cohort included 64,421 evolocumab initiators and 479,682 ezetimibe initiators. After weighting, all baseline covariates were balanced (standardized mean differences

Förderung

  • Amgen Inc

Zitieren

APA

Desai, N., Jin, R., Hurwitz, K., Dhalwani, N. N., Rathnayaka, N., Kent, S. T., Accortt, N. A., Lash, T. L., Muntner, P., Gale, C. P., Navar, A. M., & Brookhart, M. A. (2026). Real-world comparative effectiveness of evolocumab versus ezetimibe in adults with atherosclerotic cardiovascular disease: an active-comparator new-user study. American Journal of Preventive Cardiology, 102577. https://doi.org/10.1016/j.ajpc.2026.102577

Vancouver

Desai N, Jin R, Hurwitz K, Dhalwani NN, Rathnayaka N, Kent ST, et al. Real-world comparative effectiveness of evolocumab versus ezetimibe in adults with atherosclerotic cardiovascular disease: an active-comparator new-user study. American Journal of Preventive Cardiology. 2026:102577. doi:10.1016/j.ajpc.2026.102577

BibTeX
@article{Desai2026,
  author = {Desai, Nihar and Jin, Ran and Hurwitz, Kathleen and Dhalwani, Nafeesa N. and Rathnayaka, Nuvan and Kent, Shia T. and Accortt, Neil A. and Lash, Timothy L. and Muntner, Paul and Gale, Chris P. and Navar, Ann Marie and Brookhart, M. Alan},
  title = {Real-world comparative effectiveness of evolocumab versus ezetimibe in adults with atherosclerotic cardiovascular disease: an active-comparator new-user study},
  journal = {American Journal of Preventive Cardiology},
  year = {2026},
  pages = {102577},
  doi = {10.1016/j.ajpc.2026.102577}
}
Kostenlos starten →